Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive...
Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia1 moreThis phase II trial studies how well inotuzumab ozogamicin works in treating patients with B-cell acute lymphocytic leukemia with positive minimal residual disease. Inotuzumab ozogamicin is a monoclonal antibody called inotuzumab linked to a toxic agent called ozogamicin. Inotuzumab ozogamicin attaches to B cell-specific CD22 cancer cells in a targeted way and kills them.
A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION...
Colon CancerResected StageA study of immunotherapy with expanded CB-NK cells in combination with cetuximab, to evaluate activity against minimal residual disease in patients with colon cancer that have completed adjuvant treatment but are positive for ctDNA
Adjuvant Durvalumab for Early Stage NSCLC Patients With ctDNA Minimal Residual Disease
Non-small Cell Lung CancerNon-small Cell Lung Cancer Stage I2 moreIn this study circulating tumor DNA (ctDNA) blood testing is used to detect the residual blood cancer. If residual cancer using this blood test is detected there may be at higher risk of having the cancer return. The study is going to test whether or not the number of circulating cancer cells detected in the blood can be reduced by administration durvalumab after the standard treatment if you are tested positive for the residual cancer.
Evaluation of 3D Ultrasound in Brain Tumor Surgery
Residual TumorEvaluation of impact of use of 3D ultrasound in brain tumor surgery on extend of resection. Benefit for surgery, neurological outcome, accuracy and image quality are secondary outcome parameters. Control group is a retrospective matched pair cohort.
Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD
Acute Lymphoblastic Leukemiain Relapse2 moreVarious drugs have been added to different treatment regimens in order to improve the response rate in patients with Acute Lymphoblastic Leukemia, however, it has been shown that adding Bortezomib to the relapsing regimen improves the proportion of second complete remissions without increasing chemotherapy toxicity. Therefore, proteasome inhibitors can drastically modify the prognosis of patients, since their synergy with drugs such as steroids has positioned them as an attractive strategy.
DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients...
Colorectal CancerColon CancerTo learn if lifestyle changes (such as diet and exercise) combined with daily aspirin and vitamin D can affect the likelihood of advanced colorectal cancer coming back (recurring)
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People...
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)This study will find out whether people with CLL or SLL who have received treatment with venetoclax, either alone or in combination with another drug, and who are found to be MRD-negative, can stop treatment with venetoclax and remain off-treatment for 12 months or more. The researchers will also see whether study participants remain MRD-negative after they stop treatment with venetoclax.
Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse...
Multiple MyelomaPREDATOR is a study investigating a role of preemptive daratumumab therapy for preclinical relapse or progression of multiple myeloma (MM).
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations...
LymphomaTo test the feasibility of collecting cell-free DNA (cfDNA) samples from DLBCL patients before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the vein puncture method.
Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual...
Adult Acute Lymphoblastic Leukemia in Complete RemissionB Acute Lymphoblastic Leukemia2 moreThis phase II trial studies how well blinatumomab works in treating patients with B-cell acute lymphoblastic leukemia whose disease is in remission (causes no symptoms or signs) but is still present in a small number of cells in the body (minimal residual disease). Immunotherapy with monoclonal antibodies, such as blinatumomab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.